Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 5;21(2):15.
doi: 10.1007/s11864-020-0705-7.

Dedifferentiated Liposarcoma: Systemic Therapy Options

Zhubin Gahvari  1 , Amanda Parkes  2
Affiliations
Review

Dedifferentiated Liposarcoma: Systemic Therapy Options

Zhubin Gahvari et al. Curr Treat Options Oncol. .

Abstract

Over the last several years, the systemic treatment landscape for dedifferentiated liposarcoma (DDLPS) has notably expanded. Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel, that were shown to have efficacy in unselected populations of patients with soft tissue sarcomas. More recently, however, there have been phase II and III trials establishing clinical benefit of the cytotoxic agents trabectedin and eribulin along with the tyrosine kinase inhibitor pazopanib in patients with advanced liposarcoma and DDLPS. Additionally, there are several investigational targeted therapies that have incorporated advances in the understanding of DDLPS disease biology, exploiting the fact that nearly all such tumors include highly amplified expression of MDM2 and CDK4. Recent clinical trials have supported the benefit of the CDK4 inhibitor abemaciclib and the nuclear export inhibitor selinexor and support continued development of anti-MDM2 therapies, with particular attention to the bone marrow toxicity and resultant thrombocytopenia that has thus far limited their use. In contrast, the checkpoint inhibitors pembrolizumab and nivolumab remain of questionable benefit, although these immunotherapy drugs may have a role when combined with other therapeutic agents. Ongoing phase III trials will clarify the role of these novel agents. Future directions include directly comparing current standard-of-care options and newer therapies, developing synergistic combinations of novel agents, and evaluating their role in patients with localized DDLPS.

Keywords: CDK4; Chemotherapy; Dedifferentiated liposarcoma; Liposarcoma; MDM2; Metastatic.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 2018 Jan 10;36(2):151-159 - PubMed
    1. Am J Clin Pathol. 1994 Nov;102(5):677-83 - PubMed
    1. Mol Biol Cell. 1995 Apr;6(4):387-400 - PubMed
    1. Lancet Oncol. 2018 Mar;19(3):416-426 - PubMed
    1. Acta Oncol. 2017 Jul;56(7):1013-1020 - PubMed

LinkOut - more resources